FARESTON *
Manufacturer Details
SHIRE INC
Shire US Inc
Compositions:
Toremifene Citrate 60mg tablets ,
Strength
|
Rate
|
Packing Style
|
60mg
|
0.00
|
30s/100s white tablets
|
List of Related Indications:
List Of Drugs:
- Toremifene Citrate - Antiestrogens - Hormones
Indication Type Description:
Drug Interaction:
Drug interactions -summary
Thiazide diuretics-
drugs that decrease renal calcium excretion ( thiazide diuretics ) may increase risk of
hypercalcemia in patients receiving toremifene citrate
Anticoagulants-
increased coagulation time. When concomittant use of anticoagulant with toremifene
is necessary carfully monitor prothrombin time.
CYP450 isoenzymes-
cytochrome P450 enzyme inducers eg phenobarbital, carbamazepine increase
rate of toremifene metabolism.
Indication:
Breast cancer
Adverse Reaction:
Adverse reactions reported-
Dizziness 8%
Edema 4%
Hot flushes 30%
Nausea 12%
Sweating 15%
Vaginal bleeding 1%
Vaginal discharge 10%
Vomiting 3%
Contra-Indications:
Hypersensitivity to the drug
Special Precautions/Warnings-
Hypercalcemia and tumor flares-
Tumor flares have been reported in some breat cancer patients with bone metastates during first weeks of treatment. Tumor flares is often accompanied by hypercalcemia
If hypercalcemia is severe , discontinue toremifene citrate treatment
Thromboembolic disease/pre-existing endometrial hyperplasia -
Patients with a history of thromboembolic diseases should generally not be treated with toremifine citrate.
Pregnancy- appraise patient of the potenial hazard to the fetus or potential risk for loss of the pregnancy
Lactation- not known if the drug is excreted in human . Excercise caution
Children- no indication for use children.
Monitoring- periodic complete blood counts , calcium levels, and liver function tests should
be obtained.
Dosages/ Overdosage Etc:
Indication-
Breast cancer
Dosage-
Recommended dose is 60mg once daily. Treatment is generally continued until progression
is observed
Store - 25C ( 77F ). Protect from heat and light.
Patient Information:
Vaginal bleeding has been reported in patients using toremifine citrate.
Inform patients about this and instruct them to contact their physcian if such bleeding occurs.
Pregnancy and lactation:
Pregnancy-
Appraise patient of the potenial hazard to the fetus or potential risk for loss of the
pregnancy
Lactation-
Not known if the drug is excreted in human . Excercise caution
Children-
No indication for use children.